EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
07 octubre 2024
ATEZOLIZUMAB - NEUROTOXICITY Is Challenging To Recognize Due To Widely Varying Symptoms, Emphasizing The Need For a Thorough Safety Assessment To Determine The Incidence And Patient Risk Profiles .